*EPF307 07/12/00
Byliner: Fauci on Controlling AIDS Epidemic
(Cites origins of virus, ways to prevent transmission) (3960)

(This byliner appeared in the July 2000 issue of the Global Issues Electronic Journal entitled "AIDS: The Threat to World Security." Persons who intend to redistribute this byliner should give credit to The New England Journal of Medicine, September 30, 1999.)

The AIDS Epidemic: Considerations for the 21st Century
By Dr. Anthony S. Fauci

(The author is director of the U.S. National Institute of Allergy and Infectious Diseases.)

Humankind has been besieged throughout its evolution by microorganisms that pose a continual challenge to the survival of the species.(1) Although such ancient killers as tuberculosis and malaria persistently take a toll of millions of lives per year, occasionally the emergence or reemergence of a microbe results in an unexpected, catastrophic pandemic with global public health consequences. As we enter a new century, it is worth reflecting on the fact that within the framework of an enormous but constant burden of a variety of infectious diseases, as well as a number of mini-epidemics, the 20th century witnessed two such unexpected cataclysmic events.

One, the influenza A pandemic of 1918, was due to an old, but reemerging microbe. Influenza had been a problem for centuries, but in that one winter of 1918-1919 it was responsible for the deaths of approximately 25 million people worldwide and 550,000 people in the United States.(2)

The other pandemic, the acquired immunodeficiency syndrome (AIDS), is due to a newly recognized microbe, the human immunodeficiency virus (HIV).(3) The world first became aware of this new disease in the summer of 1981, and it has exploded in successive waves in various regions of the world. The catastrophic potential of the pandemic may still not have been fully realized. As this new millennium begins, it is appropriate to reflect on the origins of this epidemic, what has occurred over the past 18 years, what has been accomplished from a scientific and public health perspective, and what the prospects are for the future.

THE ORIGINS OF HIV

Recent molecular epidemiologic data have clearly indicated that HIV type 1 (HIV-1) evolved with the Pan troglodytes troglodytes subspecies of chimpanzee and was present in that subspecies for centuries.(4) The virus apparently does not readily cause disease in the chimpanzee. As is the case with many viruses, HIV at a particular point (or points) in time "jumped" species to infect human beings; hence, it almost certainly originated as a zoonotic infection. HIV type 2, the less prevalent and less virulent species of HIV, is remarkably similar genetically to the simian immunodeficiency virus that is endemic among sooty mangabeys.(5)

The most likely mechanism of transmission of HIV-1 from chimpanzees to humans was by contamination of a person's open wound with the infected blood of a chimpanzee, probably when the chimpanzee was being butchered for the purposes of consumption.(6) Chimpanzees have traditionally served as a source of nutrition for humans in certain parts of sub-Saharan Africa. Any of a number of mutations in the viral genome that would have allowed successful transmission of the virus from chimpanzees to humans probably took place intermittently over the centuries.(4) Indeed, it is likely that sporadic cases of transmission to humans were continually occurring unnoticed over the course of decades, and perhaps centuries.

Only when demographic and social conditions allowed rapid spread of the virus among people did an epidemic actually begin to emerge. These conditions included massive migration from rural areas to urban areas; the breakup of family units due to the migratory nature of employment opportunities, with its attendant sexual promiscuity and extensive frequenting of commercial sex workers; and contamination of the blood supply.(7)

The introduction of the epidemic to developed countries, such as the United States, followed relatively soon after the "gay revolution" that had its origins in the riot at the Stonewall Inn, a bar frequented by homosexual men, in New York City in 1969.(8) The demographic setting of the high-risk homosexual practices that were concentrated in cities such as New York, San Francisco, and Los Angeles in the 1970s and early 1980s unfortunately made this population of predominantly young adults a perfect target for an epidemic of sexually transmitted disease. Similar patterns soon followed in other developed countries, such as Canada, Australia, and those of western Europe.

SCOPE OF THE EPIDEMIC

AIDS continues to exact an enormous toll throughout the world, in both human and economic terms. In the United States, an estimated 650,000 to 900,000 people are infected with HIV,(9) of whom more than 200,000 are unaware of their infection.(10) Through 1998 (the latest figures available), 688,200 cumulative cases of AIDS and 410,800 AIDS-related deaths had been reported to the Centers for Disease Control and Prevention (CDC).(11)

The demographic characteristics of those affected by the epidemic have changed dramatically since the first cases were reported in 1981. Unlike the early days of the HIV and AIDS epidemic in the United States, when the affected population consisted overwhelmingly of homosexual men, leading some to assume incorrectly that the epidemic would remain contained within the gay population, today new cases of HIV infection result predominantly from injection-drug use and heterosexual contact, with a disproportionate representation among minority populations.(11) The numbers of cases of AIDS (per 100,000 population) reported in 1998 in the United States were 66.4 for non-Hispanic blacks, 28.1 for Hispanics, 8.2 for non-Hispanic whites, 7.4 for American Indians and Alaska Natives, and 3.8 for Asians and Pacific Islanders. Women are increasingly affected; the proportion of U.S. cases reported among women and adolescent girls more than tripled between 1985 and 1998, from 7 percent to 23 percent.(11)

It is often said that the HIV and AIDS epidemic in the United States and other developed countries has reached a plateau, since the number of new infections per year is no longer on an accelerating trajectory but has leveled off. However, in the United States it is estimated that this plateau has reached an unacceptable level of 40,000 new infections per year, a rate that is believed to have remained relatively constant throughout the 1990s.(12) Of these newly infected people, the CDC estimates that half are younger than 25 years of age and were infected sexually.(13) As the number of new cases per year among homosexual men has decreased dramatically, the number of new infections among heterosexuals, particularly among women, has accelerated greatly, producing a deceptive plateau. In the United States we are in fact seeing new waves of the epidemic among different demographic groups.

The same phenomenon of successive waves is reflected dramatically in the global pattern of the epidemic, with sub-Saharan Africa currently bearing the greatest burden of the epidemic worldwide.(14) In addition, the number of HIV infections in the countries of the former Soviet Union has escalated sharply over the past few years.(14) However, the trajectory of the infection rate in the Indian subcontinent and Southeast Asia indicates that without dramatically successful preventive measures, these regions will bear the greatest burden of the epidemic as we enter the 21st century.(14) The estimated number of infections in China is still relatively low; however, there is potential for an explosive spread of HIV in that nation of more than 1 billion people.

The magnitude of the epidemic is huge. As of the end of 1998, there were more than 33 million people worldwide with HIV infection or AIDS, 43 percent of them female, according to estimates by the Joint United Nations Program on HIV/AIDS (UNAIDS).(14) An estimated 5.8 million new HIV infections occurred worldwide during 1998 -- approximately 16,000 each day. More than 95 percent of these new infections occurred in developing countries. In 1998, HIV infection or AIDS was the fourth leading cause of death worldwide, resulting in an estimated 2.3 million deaths.(15) If the current trend in the incidence of HIV infection continues, more than 40 million people will be infected with HIV as we enter the new millennium.

THE SUCCESSES AND LIMITATIONS OF ANTIRETROVIRAL THERAPY

In the United States and other developed countries, the numbers of new AIDS diagnoses and deaths have fallen substantially during the past three years. The age-adjusted death rate from AIDS declined 48 percent from 1996 to 1997(16); similar decreases have been noted in western Europe and Australia.(17,18) These trends are due to several factors, including improved prophylaxis against opportunistic infections and improved treatment, the growing experience among health professionals in caring for HIV-infected patients, improved access to health care, and the decrease in the number of new HIV infections due to prevention efforts and to the fact that a substantial proportion of persons with high-risk behavior are already infected.

However, the most influential factor has clearly been the increased use of potent anti-HIV drugs, generally administered in combinations of three or more agents and usually including a protease inhibitor.(17,19-21) Such combinations are known as highly active antiretroviral therapy. The development of therapies for HIV infection has been remarkably successful, reflecting an effective synergy among government, industry, and academia. Sixteen anti-HIV drugs are now licensed by the U.S. Food and Drug Administration. These drugs have had dramatic effects in reversing the extent of illness in many patients with advanced disease, as well as in preventing the progression of disease in those who are relatively healthy.

Consensus guidelines have been developed for the use of highly active antiretroviral therapy in adults and adolescents, as well as in children and in HIV-infected pregnant women.(22-24) These guidelines, when appropriately applied, have greatly improved the prognosis for HIV-infected people and have markedly reduced the risk of HIV transmission from mother to baby.

Despite the enormous beneficial effects of highly active antiretroviral therapy, many HIV-infected people have unfortunately not had adequate responses to the regimens, cannot tolerate the toxic effects, or have difficulty complying with treatment that involves large numbers of pills, myriad interactions with other drugs, and complicated dosing schedules in which intake of food and liquids must be taken into account.(22) Even in patients who are successfully treated with highly active antiretroviral therapy and have extremely low levels of HIV-1 ribonucleic acid (RNA) in plasma, the virus persists in sanctuaries where the drugs cannot reach it or in a latent form on which drugs have no effect.(25-28) In addition, the emergence of strains of HIV that are resistant to currently available drugs is a widespread and growing problem.(29)

Although there is evidence of improvement in immune-system function in most patients who receive combination antiretroviral therapy, complete normalization of the immune system and complete eradication of the virus from the body appear unlikely with currently available therapies. The persistence of latent HIV despite therapy that successfully suppresses detectable levels of HIV-1 RNA in plasma is particularly problematic and suggests that lifelong treatment may be necessary with drugs that are currently expensive and difficult to tolerate for prolonged periods.(30-34) In patients in whom plasma HIV-1 RNA had been suppressed by highly active antiretroviral therapy to below detectable levels for a median of 390 days, levels invariably rebounded within three weeks after the cessation of therapy.(35)

Therefore, the development of a new generation of therapies remains a major priority. Currently, all licensed antiretroviral medications are directed at one of two viral enzymes, reverse transcriptase or protease. Many new treatment strategies are being developed and tested, including the use of drugs that prevent the virus from entering a cell and those that prevent the integration of the provirus into nuclear DNA. In addition, approaches to purging the virus from its latent reservoirs in certain cells and tissues are being vigorously pursued, as are methods to boost HIV-specific immune responses.(36)

PREVENTION OF HIV INFECTION

In developing countries in which the per capita allocation for health care spending may be only a few dollars a year, anti-HIV therapies are invariably beyond the reach of all but the privileged few. This situation underscores the need for effective, low-cost tools for HIV prevention that can be used in these settings as well as in the United States and other developed countries. Even if such therapies were feasible on a global scale, it is clear that treatment is not the solution to the global HIV problem. Unlike microbial scourges, such as malaria and tuberculosis (among many others), for which there is very little that people can do to prevent infection, HIV infection in adults is entirely preventable by behavior modification. Researchers have shown that several approaches to prevention, when properly executed, can be effective. These approaches include education and behavior modification, the promotion and provision of condoms, the treatment of other sexually transmitted diseases, drug-abuse treatment (for example, methadone maintenance for injection-drug users), access to clean needles and syringes for injection-drug users, and the use of antiretroviral drugs to interrupt the transmission of the virus from mother to infant.(37)

The use of antiretroviral drugs in pregnant women with HIV infection and their infants is an extraordinarily successful prevention strategy.(38) The rate of mother-to-child transmission of HIV in the United States has been cut to negligible levels among women and infants treated with an extended regimen of zidovudine therapy. Recent studies by the CDC, the National Institutes of Health (NIH), and others have shown that substantially shorter regimens of antiretroviral drugs, which would be more feasible in poorer countries, can also reduce perinatal HIV transmission dramatically.(39-40) A brief and affordable regimen of therapy administered to the mother around the time of delivery could potentially prevent HIV infection in hundreds of thousands of babies per year. An interim analysis of a study in Uganda indicates that two doses of nevirapine -- one given to the mother at the onset of labor and one given to the infant within 72 hours after birth -- can markedly reduce the incidence of perinatal transmission of HIV.(41)

Other methods of preventing HIV transmission may also help slow the epidemic of HIV and AIDS. For example, researchers are developing and testing topical microbicides, substances that a woman could use in her vagina before sexual intercourse to prevent the transmission of HIV and other sexually transmitted diseases.(42) UNAIDS and other organizations have also facilitated the widespread use of the female condom in Africa. These interventions may help empower women to protect themselves in situations in which they are unable to avoid sexual relations with HIV-infected partners or cannot persuade their partners to use a condom.

DEVELOPMENT OF AN HIV VACCINE

Historically, vaccines have provided a safe, cost-effective, and efficient means of preventing illness, disability, and death from infectious diseases.(43) The solution to the HIV pandemic is the development and availability of a safe and effective vaccine against the infection. Indeed, such a goal remains the highest priority of AIDS research. A major scientific obstacle to the accomplishment of this goal has been the difficulty in establishing the precise correlates of protective immunity against HIV infection. To speed the pace of discovery, many public and private agencies have dramatically increased the resources devoted to research on HIV vaccines. For example, at the NIH, funding for HIV-vaccine research rose from $100.5 million in fiscal year 1995 to an estimated $194.1 million in fiscal year 1999. To date, more than 3,000 uninfected volunteers have enrolled in more than 50 HIV-vaccine studies sponsored by the NIH (including two phase 2 intermediate-sized trials), involving 27 vaccines.

As part of a broad portfolio of research, recent NIH-supported studies have assessed so-called vectored vaccines: harmless viruses (e.g., canarypox) that are genetically altered to make HIV proteins. These vaccines have been administered to volunteers in combination with a separate vaccine made of a purified HIV envelope protein. Results have been encouraging. In phase 1 and phase 2 studies, the combination approach has appeared safe and has evoked both cellular and humoral immune responses that may have a role in providing protection from HIV infection.(44) Three vectors, as well as other HIV proteins, are currently being compared to determine which combination produces the most vigorous immune response.

Meanwhile, a large-scale study of a vaccine based on the surface proteins of two strains of HIV was recently undertaken in the United States by a private company, with an additional phase 3 study to be conducted in Thailand.(45) Finally, a phase 1 trial of canarypox-vectored vaccine for HIV infection has been initiated in Uganda in a growing effort to involve scientists from developing countries in the research effort.

CONCLUSIONS

The HIV pandemic has posed a formidable challenge to the biomedical-research and public health communities of the world. What began as a handful of recognized cases among homosexual men in the United States has become a global pandemic of such proportions that it clearly ranks as one of the most destructive microbial scourges in history. We are at a pivotal point in the evolution of this historic event. Biomedical research has provided the tools for the development of treatments as well as a still elusive vaccine. It has become apparent over the past few years that minimizing the destructive impact of this epidemic will require partnerships between the public and private sectors as well as a stronger political will among the nations of the world. Unless methods of prevention, with or without a vaccine, are successful, the worst of the global pandemic will occur in the 21st century.

REFERENCES

1. Krause RM. Introduction to infectious diseases: stemming the tide. In: Krause RM, ed. Emerging infections. New York: Academic Press, 1998: 1-22.

2. History of influenza. In: Kilbourne ED. Influenza. New York: Plenum Medical Book, 1987:3-22.

3. Fauci AS. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 1988;239:617-22.

4. Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes, Nature 1999;897:436-41.

5. Hirsch VM, Olmsted RA, Murphey-Corb M, Purcell, RH, Johnson PR. An African primate lentivirus (SIVsm) closely related to HIV-2. Nature 1989;339:389-92.

6. Weiss RA, Wrangham RW. From Pan to pandemic. Nature 1999;397:385-6.

7. Quinn TC, Fauci AS. The AIDS epidemic: demographic aspects, population biology, and virus evolution. In: Krause RM, ed. Emerging infections. New York: Academic Press, 1998:327-63.

8. Kramer L. Reports from the holocaust: the story of an AIDS activist. London: Cassell, 1994.

9. Karon JM, Rosenberg PS, McQuillan G, Khare M, Gwinn M, Petersen LR. Prevalence of HIV infection in the United States, 1984 to 1992. JAMA 1996;276:126-31.

10. Sweeney PA, Fleming PL, Karon JM, Ward JW. Minimum estimate of the number of living HIV infected persons confidentially tested in the United States. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28-October 1, 1997. Washington, D.C.: American Society for Microbiology, 1997:245. abstract.

11. HIV/AIDS surveillance report. Vol. 10. No. 2. Atlanta: Centers for Disease Control and Prevention, 1998:1-48.

12. Rosenberg PS. Scope of the AIDS epidemic in the United States. Science 1995;270:1372-5.

13. Rosenberg PS, Biggar RJ, Goedert JJ. Declining age at HIV infection in the United States. N Engl J Med 1994;330:789-90.

14. AIDS epidemic update: December, 1998. Geneva: Joint United Nations Program on HIV/AIDS (UNAIDS), World Health Organization, 1998.

15. The World Health Report 1999: Making a Difference. Geneva: World Health Organization, 1999.

16. Hoyert DL, Kochanek KD, Murphy SL. Deaths: final data for 1997 Natl Vital Stat Rep 1999;47(19):1-104.

17. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-30.

18. Dore GJ, Brown T, Tarantola D, Kaldor JM. HIV and AIDS in the Asia-Pacific region: an epidemiological overview. AIDS 1998;12:Suppl B:S1-S10.

19. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.

20. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999;179:717-20.

21. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998;280:1497-503.

22. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998;47(RR-5):43-82, (See updates at http://www.hivatis.org.)

23. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR Morb Mortal Wkly Rep 1998;47(RR-4):I-43. (See updates at http://www.hivatis.org.)

24. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep 1998;47(RR-2):1-30. (See updates at http://www.hivatis.org.)

25. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 1998;95:8869-73.

26.. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997;94:13193-7.

27. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir of HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-300.

28. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5.

29. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 1999;353:2195-9.

30. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999;340:1614-22.

31. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605-13.

32. Pomerantz RJ, Residual HIV-1 disease in the era of highly active antiretroviral therapy. N Engl J Med 1999;340:1672-4.

33. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-7,

34. Chun TW, Engel D, Mizell SB, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 1999;5:651-5.

35. Harrigan PR, Whaley M, Montaner JS. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999;13:F59-F62.

36. Cooper DA, Emery S. Latent reservoirs of HIV infection: flushing with IL-2? Nat Med 1999;5:611-2.

37. Coates TJ, Collins C. Preventing HIV infection. Sci Am 1998;279:96-7.

38. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.

39. Mofenson LM. Short-course zidovudine for prevention of perinatal infection. Lancet 1999;353:766-7

40. Saba J. The results of the PETRA intervention trial to prevent perinatal transmission in sub-Saharan Africa. Chicago: Foundation for Retrovirology and Human Health, 1999. (See http://www.retroconference.org/99/lect_symposia/sym_session8.htm.) (See NAPS document no. 05531 for 19 pages, c/o Microfiche Publications, 248 Hempstead Tpke., West Hempstead, NY 11552.)

41. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354;795-802.

42. Elias C, Coggins C. Female-controlled methods to prevent sexual transmission of HIV. AIDS 1996;10:Suppl 3:S43-S51.

43. Folkers GK, Fauci AS. The role of US government agencies in vaccine research and development. Nat Med 1998;4:Suppl:491-4.

44. Evans TG, Keefer MC, Weinhold KJ, et al. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp 120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999;180:290-8.

45. Francis DP, Gregory T, McElrath MJ, et al. Advancing AIDSVAX to phase 3: safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses 1998;14:Suppl 3:S325-S331.

(Reprinted by permission from The New England Journal of Medicine, September 30, 1999. Copyright (c) 1999, Massachusetts Medical Society.)

*EPF308 07/12/00
Officials Grapple with How to Expand AIDS Treatment in Poor Nations
(Science is strong, but policy choices difficult)(650)
By Charlene Porter
Washington File Staff Correspondent

Durban, South Africa -- Improvements in AIDS treatment are within reach in the developing world, according to officials with the U.S. Centers for Disease Control and Prevention (CDC), who presented their latest findings at the XIII International AIDS Conference underway in Durban, South Africa.

CDC researchers July 12 summarized the findings of studies in Ivory Coast and Thailand examining the administration of antiretroviral drugs to prevent mother-to-child transmission of the HIV virus that causes AIDS. Both studies produced results in reducing transmission that the scientists considered significant.

"I think these studies show the possibilities of prevention," Dr. Helene Gayle, director of CDC's National Center for HIV, STD and Tuberculosis Prevention, told a Durban news conference.

Each year, HIV mothers pass on the infection to 600,000 infants. A baby may become infected in utero, during the birth process or through breast-feeding. The use of antiretroviral drugs before birth can prevent transmission. Gayle said a 75 percent reduction has been achieved in the United States.

CDC researchers attribute those transmissions that still do occur to mothers who are unaware of their HIV status or are involved in some form of substance abuse.

The Thailand study involved joint work between CDC and the Thai government in which more than 60,000 pregnant women were tested for HIV infection. Of the 552 who tested HIV-positive, almost 67 percent took antiretroviral drugs.

CDC researcher R.J. Simonds said successful implementation of the testing program over a broad, rural geographic region of Thailand proved that incorporating HIV testing and treatment into existing perinatal care systems is possible and affordable. He said that Thai officials are currently gearing up to extend the program nationwide based on this experience.

The question of how to expand the availability of HIV treatments to the developing world is a major issue on the agenda at the AIDS conference. High costs and the need for sophisticated medical infrastructure are two of the major obstacles that prevent the delivery of antiretroviral drugs to AIDS victims living in poor nations. These treatments have worked to reduce the opportunistic infections of AIDS and prolong life for many HIV-infected people in Western Europe and the United States.

Gayle said the scientific data provides strong proof that antiretrovirals can prevent mother-to-child transmission of HIV. She added, "I think applying scientific data to practical, real-world problems with multiple, competing priorities in poor countries is a whole other issue .... Moving science into practice and into policy is not as straightforward."

CDC researchers this week also presented findings about the treatment of HIV patients in Abidjan, Ivory Coast, with Highly Active Antiretroviral Therapy, known as HAART. Just as in the developed world, the limited drug trial did prove effective for the patients involved under the supervision of well-trained medical professionals working in one of West Africa's most urbanized areas.

Top international health officials have emphasized that dropping the price of the antiretroviral drugs is not the only answer to increasing their availability. But Gayle emphasized that medical infrastructure in some developing world cities is adequate to provide the support that HAART patients need. "In some of the cities," Gayle said, "dropping the price is the only issue."

Gayle said health policy-makers in the developing world must struggle with the difficult questions of achieving equity in medical care for all citizens, or providing advanced treatments for those few who may have better access to sophisticated care under existing conditions.

Helping developing world nations build better medical infrastructure is one of the primary objectives of U.S. programs to help poor countries deal with the AIDS epidemic.

(The Washington File is a product of the Office of International Information Programs, U.S. Department of State. Web site: http://usinfo.state.gov)
NNNN